Learn about the global alpha mannosidosis market through The Business Research Company, which provides information on alpha mannosidosis market size, alpha mannosidosis market drivers and restraints, alpha mannosidosis market players, the COVID-19 impact on the alpha mannosidosis market, and more.

The global alpha mannosidosis market reached a value of nearly $7.60 million in 2020 to $70.06 million in 2025 at a rate of 55.9%. The alpha mannosidosis market is then expected to grow at a CAGR of 15.4% from 2025 and reach $143.14 million in 2030.

The increasing investments on research is expected to drive innovation in alpha mannosidosis, thus driving the market during the forecast period.

Request A Sample For The Global Alpha Mannosidosis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5537&type=smp

The alpha mannosidosis market consists of sales of therapies for alpha mannosidosis by entities (organizations, sole traders and partnerships) that provide treatment for alpha mannosidosis. Alpha-mannosidosis (a-mannosidosis) is a rare lysosomal storage disorder with an autosomal recessive inheritance caused by mutations in the gene encoding for the lysosomal a-d-mannosidase. Lysosomes are particles bound in membranes within cells that function as the primary digestive units. Key therapies in the treatment of Alpha Mannosidosis include enzyme replacement therapy and bone marrow transplants.

Global Alpha Mannosidosis Market Segments Include:

By Therapy Type: Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT), Peripheral Blood Stem Cell Transplantation (PBSCT), Gene Therapy

By Indication: Type I, Type II, Type III

By End-User: Hospitals, Speciality Clinics

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America was the largest region in the alpha mannosidosis market in 2020.

The use of enzyme replacement therapy is increasingly gaining traction in the alpha mannosidosis market. Lamzede (velmanase alfa) is a long-term enzyme replacement therapy in adults, adolescents, and children to help treat mild to moderate forms of alpha-mannosidosis. It is a recombinant human alpha-mannosidase developed as an intravenous enzyme replacement therapy (ERT) to administer the medicine into the bloodstream in order to replace the function of the deficient enzyme in the body. The therapy aims to normalize oligosaccharide levels in the body, which ultimately prevents the progression of the disease and the formation of abnormalities.

TBRC’s alpha mannosidosis market report covers:

Major Market Players: Chiesi Farmaceutici S.p.A.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2015-20) and ten years forecast (2021-2025-2030)

The Alpha Mannosidosis Global Market Report 2022: Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides alpha mannosidosis market overviews, analyses and forecasts market size, share, alpha mannosidosis market players, alpha mannosidosis market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s alpha mannosidosis market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here Is A List Of Similar Reports From The Business Research Company:

Hematology Diagnostic Devices And Equipment Global Market Report 2021

Cell And Gene Therapy Market

Gene Therapy Global Market Report 2021

Interested To Know More About The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: